For instance, clinical trials exploring the combination of CAR-T cells with immune checkpoint inhibitors, such as anti-PD-1 or anti-CTLA-4 antibodies, could enhance therapeutic efficacy by overcoming the immunosuppressive tumor microenvironment. This evidence concerns the gene CTLA4 and neoplasm.